Live
FierceBiotechADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospectFierceBiotechADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetesClinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune DiseaseCellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvationCellReplaying germinal center evolution on a quantified affinity landscapeCellXenophagocytosis blockade enhances interspecies chimerismFierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buyEndpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetesEndpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearEndpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and moreFierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs
Agilent 12 déc. 2025

Strength in Technology Enabled Products Drives Roper: Can It Sustain? - The Globe and Mail

Strength in Technology Enabled Products Drives Roper: Can It Sustain? - The Globe and Mail

Original
Contenu indisponible. Consultez la source originale.